NO20003546L - Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse - Google Patents

Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse

Info

Publication number
NO20003546L
NO20003546L NO20003546A NO20003546A NO20003546L NO 20003546 L NO20003546 L NO 20003546L NO 20003546 A NO20003546 A NO 20003546A NO 20003546 A NO20003546 A NO 20003546A NO 20003546 L NO20003546 L NO 20003546L
Authority
NO
Norway
Prior art keywords
progestin
well
pharmaceutical composition
kit containing
dehydroepiandrosterone
Prior art date
Application number
NO20003546A
Other languages
English (en)
Other versions
NO20003546D0 (no
Inventor
Fernand Labrie
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/180,361 external-priority patent/US5776923A/en
Publication of NO20003546L publication Critical patent/NO20003546L/no
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Publication of NO20003546D0 publication Critical patent/NO20003546D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Lubricants (AREA)
  • Dental Preparations (AREA)

Abstract

Forløpere av kjønnssteroid så som dehydroepiandrosteron og dehydroepiandrosteronsulfat og forbindelser om- dannet In vlvo, blir anvendt for fremstilling av et medikament i kombinasjon med et progestin for behand- ling av menopause.
NO20003546A 1993-01-19 2000-07-10 Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse NO20003546D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US561993A 1993-01-19 1993-01-19
US08/180,361 US5776923A (en) 1993-01-19 1994-01-18 Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
PCT/CA1994/000022 WO1994016709A2 (en) 1993-01-19 1994-01-19 Therapeutic uses and delivery systems of dehydroepiandrosterone

Publications (2)

Publication Number Publication Date
NO20003546L true NO20003546L (no) 1995-06-16
NO20003546D0 NO20003546D0 (no) 2000-07-10

Family

ID=26674550

Family Applications (6)

Application Number Title Priority Date Filing Date
NO952417A NO952417L (no) 1993-01-19 1995-06-16 Terapeutiske anvendelser og leveringssystemer for dehydroepiandrosteron
NO20003549A NO314656B1 (no) 1993-01-19 2000-07-10 Anvendelse av DHEA til forebygging og/eller behandling av hudatrofi
NO20003547A NO315690B1 (no) 1993-01-19 2000-07-10 Anvendelse av DHEA og DHEA-S for fremstilling av et medikament til behandling etter reduksjon av ubalanserte konsentrasjoner avkjönnssteroider
NO20003546A NO20003546D0 (no) 1993-01-19 2000-07-10 Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse
NO20003545A NO314067B1 (no) 1993-01-19 2000-07-10 Farmasöytisk sammensetning for perkutan eller transmukosal avlevering, samtet transdermalt plaster
NO20024189A NO321846B1 (no) 1993-01-19 2002-09-03 Anvendelse av kjonnssteroidforlopere eller DHEA til fremstilling av et medikament til forebygging eller behandling av vaginal atrofi eller hypogonadisme

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NO952417A NO952417L (no) 1993-01-19 1995-06-16 Terapeutiske anvendelser og leveringssystemer for dehydroepiandrosteron
NO20003549A NO314656B1 (no) 1993-01-19 2000-07-10 Anvendelse av DHEA til forebygging og/eller behandling av hudatrofi
NO20003547A NO315690B1 (no) 1993-01-19 2000-07-10 Anvendelse av DHEA og DHEA-S for fremstilling av et medikament til behandling etter reduksjon av ubalanserte konsentrasjoner avkjönnssteroider

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20003545A NO314067B1 (no) 1993-01-19 2000-07-10 Farmasöytisk sammensetning for perkutan eller transmukosal avlevering, samtet transdermalt plaster
NO20024189A NO321846B1 (no) 1993-01-19 2002-09-03 Anvendelse av kjonnssteroidforlopere eller DHEA til fremstilling av et medikament til forebygging eller behandling av vaginal atrofi eller hypogonadisme

Country Status (18)

Country Link
US (7) US5948434A (no)
EP (1) EP0680327B1 (no)
JP (1) JP3441730B2 (no)
CN (2) CN1439375B (no)
AT (2) ATE275957T1 (no)
AU (2) AU686120B2 (no)
CZ (1) CZ297860B6 (no)
DE (2) DE69434697T2 (no)
DK (1) DK0680327T3 (no)
ES (2) ES2227523T3 (no)
FI (1) FI953017L (no)
HU (1) HU228385B1 (no)
IL (1) IL108371A (no)
NO (6) NO952417L (no)
NZ (2) NZ250712A (no)
PT (2) PT1382340E (no)
SK (1) SK286051B6 (no)
WO (1) WO1994016709A2 (no)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
FR2729854A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US7169768B1 (en) * 1997-03-18 2007-01-30 Weisman Kenneth M Method of decreasing atherosclerosis and its complications
US5912240A (en) 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
IT1291141B1 (it) * 1997-04-16 1998-12-29 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente una alcanoil l-carnitina, atta a stimolare la moltiplicazione e la crescita degli osteoblasti
US6140315A (en) * 1997-06-09 2000-10-31 Weisman; Kenneth M. Therapeutic uses of goserelin acetate
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6093389A (en) * 1997-12-01 2000-07-25 American Cyanamid Company Methods and compositions for attracting and controlling termites
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
MXPA00012304A (es) 1998-06-11 2003-05-15 Endorech Inc Composiciones farmaceuticas y usos para el androst-5-ene-3beta, 17 beta-diol.
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
FR2789312B1 (fr) * 1999-02-05 2003-10-17 Seporga Sterol 3 sulfates, nouveaux principes actifs a usage cosmetique et dermatologique, et leurs applications
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
RU2220727C2 (ru) * 1999-03-18 2004-01-10 Дженелабс Текнолоджис, Инк. Композиция, содержащая дегидроэпиандростерон, и способы ее изготовления и применения
CN1250563C (zh) 1999-05-04 2006-04-12 斯特拉坎有限公司 雄激素糖苷及其产生雄性征的活性
US6583129B1 (en) * 1999-06-11 2003-06-24 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women
AU2004222794B2 (en) * 1999-06-11 2007-03-08 Watson Pharmaceuticals, Inc. Non-oral androgenic steroids for women
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
FR2803750B1 (fr) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
FR2807323A1 (fr) 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
AU2001285367B2 (en) * 2000-08-30 2006-05-18 Besins Healthcare Luxembourg Sarl Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
WO2002085297A2 (en) * 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US20050070487A1 (en) * 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
FR2826011B1 (fr) * 2001-06-14 2004-12-10 Oreal Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique
KR100988542B1 (ko) * 2001-06-18 2010-10-20 노벤 파머수티컬즈, 인코퍼레이티드 경피 시스템에서의 강화된 약물 전달
FR2828100B1 (fr) * 2001-08-02 2004-09-24 Galderma Res & Dev Composition de type emulsion inverse contenant de la dhea et/ou ses precurseurs ou derives, et ses utilisations en cosmetique et en dermatologie
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US6805878B2 (en) * 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
PT1443966E (pt) * 2001-11-15 2007-06-21 Pantarhei Bioscience Bv Método para a prevenção ou tratamento das doenças ginecológicas benignas
WO2003070253A1 (en) * 2002-02-21 2003-08-28 Pantarhei Bioscience B.V. Estrogenic component for treating decreased libido in women
EP1494679A4 (en) * 2002-04-03 2009-10-28 Barr Lab Inc STEP-BY-STEP ESTROGENTHERAPY
AU2003224561A1 (en) * 2002-04-23 2003-11-10 Sahltech I Goteborg Ab Use of dhea for treatment of female hypopituitarism
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
EP1553954A4 (en) * 2002-06-17 2009-12-23 Epigenesis Pharmaceuticals Llc DIHYDRATE DEHYDROEPIANDROSTERONE AND METHOD FOR THE TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE LUNG DISEASE, COMPOSITIONS THEREOF
MXPA05010871A (es) * 2003-04-11 2005-11-25 Barr Lab Inc Metodos para administrar estrogenos y progestinas.
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US8147472B2 (en) 2003-11-24 2012-04-03 Kimberly-Clark Worldwide, Inc. Folded absorbent product
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
US8835413B2 (en) * 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
AU2005301035A1 (en) * 2004-11-01 2006-05-11 Endorecherche, Inc. Use of androgens to reduce the likelihood of acquiring or to treat skin aging
DE602006020353D1 (de) * 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
US8084446B2 (en) * 2005-04-26 2011-12-27 Eric Marchewitz Use of DHEA derivatives for enhancing physical performance
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US9381193B2 (en) * 2011-04-01 2016-07-05 Washington University Contraceptive methods and compositions
US9066956B2 (en) 2011-12-29 2015-06-30 Universidad De Chile Vaginal ring comprising DHEA or DHEA sulfate and optionally a release-modulating agent of the active principle, useful to increase the ovarian reserve in women and to relieve symptoms associated with menopause
US10076483B2 (en) * 2013-10-15 2018-09-18 Chelac Holding Gmbh Steroid carboxylic acid esters, compositions containing steroid carboxylic acid esters, and use of said compositions in local topical applications for cosmetic or dermatological purposes
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CA2965372C (en) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
JP2018534291A (ja) 2015-10-22 2018-11-22 ハバフ セラピューティクス ピーティーワイ エルティーディー マンモグラフィ乳房密度及び／又は乳癌のリスクを低下させる方法
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use
US11690852B2 (en) 2020-12-01 2023-07-04 Endorecherche. Inc. Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK122125B (da) * 1967-10-04 1972-01-24 Schering Ag Analogifremgangsmåde til fremstilling af terapeutisk aktive carboxylsyreestere af 3β-hydroxy-5-androstan-17-on(dehydroepiandrosteron) med 7-11 carbonatomer i esterresten.
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3661941A (en) 1970-10-09 1972-05-09 Jerry R Dias Process for preparation of 3beta-hydroxy a/b cis steroids of the cholestane series
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
JPS505372A (no) * 1973-05-30 1975-01-21
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4005200A (en) * 1975-07-17 1977-01-25 Kanebo, Ltd. Method for improving the maturity of the parturient canal and the sensitivity to oxytocin
DE2534911C2 (de) * 1975-08-01 1985-04-18 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von 5-Androsten-17-on-Derivaten
US4213978A (en) * 1978-12-05 1980-07-22 Interx Research Corporation Anti-acne and anti-seborrhea prodrug derivatives of progesterone
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US4397782A (en) * 1982-05-28 1983-08-09 E. R. Squibb & Sons, Inc. Antiinflammatory 17-spiroandrostenes
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
SE8303031D0 (sv) * 1983-05-30 1983-05-30 Leo Ab Improved steroid esters preparation
US4518595A (en) 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
EP0209590A1 (en) * 1985-01-25 1987-01-28 Monell Chemical Senses Center The use of male essence, including androstenol and dehydroepiandrosterone sulfate to treat luteal phase defects and failure to ovulate in human females
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US4812447A (en) * 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
JPS63104924A (ja) * 1986-10-20 1988-05-10 Kanebo Ltd 膣坐剤
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
JPS63267722A (ja) * 1987-04-27 1988-11-04 Daiichi Yakuhin Sangyo Kk 抗肥満症剤
US4835147A (en) 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
DE3888269T2 (de) * 1987-09-24 1994-07-07 Jencap Research Ltd Hormon-Zusammensetzung und -Anwendung.
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) * 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5047244A (en) 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
CA2004203A1 (en) * 1988-12-01 1990-06-01 Sharad K. Govil Compositions for transdermal delivery of estradiol
ZA901847B (en) * 1989-03-10 1991-10-30 Endorecherche Inc Combination therapy for the treatment of estrogen sensitive diseases
ATE230994T1 (de) * 1989-07-07 2003-02-15 Endorech Inc Methode zur behandlung androgenbedingter krankheiten
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
GB9003939D0 (en) * 1990-02-21 1990-04-18 Imperial College Sulphatase inhibitors
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5110810A (en) * 1991-02-08 1992-05-05 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására

Also Published As

Publication number Publication date
NO20024189D0 (no) 2002-09-03
DK0680327T3 (da) 2005-01-03
PT680327E (pt) 2004-12-31
CZ297860B6 (cs) 2007-04-18
DE69433994T2 (de) 2005-09-22
SK286051B6 (sk) 2008-02-05
NO315690B1 (no) 2003-10-13
ATE275957T1 (de) 2004-10-15
JP3441730B2 (ja) 2003-09-02
CN1439375A (zh) 2003-09-03
NO952417D0 (no) 1995-06-16
US5843932A (en) 1998-12-01
US5948434A (en) 1999-09-07
ATE322271T1 (de) 2006-04-15
US5798347A (en) 1998-08-25
HU228385B1 (en) 2013-03-28
CN1116823A (zh) 1996-02-14
NO20003545L (no) 1995-06-16
AU686120B2 (en) 1998-02-05
SK77995A3 (en) 1997-04-09
CZ156595A3 (en) 1995-12-13
CN1100541C (zh) 2003-02-05
EP0680327B1 (en) 2004-09-15
NO314656B1 (no) 2003-04-28
NO20003547L (no) 1995-06-16
NO321846B1 (no) 2006-07-10
NO20003546D0 (no) 2000-07-10
NO952417L (no) 1995-06-16
US5872114A (en) 1999-02-16
AU5388494A (en) 1994-07-28
FI953017A7 (fi) 1995-06-19
DE69434697D1 (de) 2006-05-18
US5807849A (en) 1998-09-15
NO20003549L (no) 1995-06-16
HUT73241A (en) 1996-07-29
ES2227523T3 (es) 2005-04-01
WO1994016709A2 (en) 1994-08-04
NO20003547D0 (no) 2000-07-10
JPH08505629A (ja) 1996-06-18
FI953017A0 (fi) 1995-06-19
EP0680327A1 (en) 1995-11-08
FI953017L (fi) 1995-06-19
HU9501985D0 (en) 1995-09-28
US5854229A (en) 1998-12-29
NO20003549D0 (no) 2000-07-10
IL108371A0 (en) 1994-04-12
NO314067B1 (no) 2003-01-27
NZ512334A (en) 2005-05-27
NO20024189L (no) 1995-06-16
WO1994016709A3 (en) 1994-11-24
IL108371A (en) 2009-09-01
NZ250712A (en) 1996-11-26
AU5855794A (en) 1994-08-15
PT1382340E (pt) 2006-07-31
NO20003545D0 (no) 2000-07-10
DE69433994D1 (de) 2004-10-21
US5837700A (en) 1998-11-17
CN1439375B (zh) 2012-08-08
ES2261836T3 (es) 2006-11-16
DE69434697T2 (de) 2007-03-29

Similar Documents

Publication Publication Date Title
NO20003546L (no) Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
MXPA02011632A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
ES2189784T3 (es) Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
DE60129550D1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
ES2042725T3 (es) Procedimiento para preparar inhibidores de 5-alfa-estersa de esteroide.
TR200001203T2 (tr) Yeni birleşik maddeler
BR9509155A (pt) Apilcação de inibidores de aromatase para preparação de um medicamento para tratamento de uma deficiência relativa de andrôgeno no homem
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
NO985232L (no) Androstenderivater
NO305273B1 (no) Sukkerbelagt farmas°ytisk doseringsenhet omfattende et steroid og anvendelse derav
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
BRPI0408944A (pt) método para fornecer um benefìcio de redução de esteróide com um inibidor de ciclooxigenase-2 e composições com este
NZ326345A (en) Composition containing diosgenin
MX9300205A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
PA8496701A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2] oct- 3 - ilamina y sus composiciones farmaceuticas
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
HUP0004461A2 (hu) Apoliprotein B kiválasztást/mikroszomális trigliceridtranszfer-proteint gátló anyag alkalmazása gyógyászati készítmények előállítására és a fenti gyógyászati készítmények

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application